Tarapeutics Science Inc. has identified phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD) and systemic lupus erythematosus.

Medshine Discovery Inc. has synthesized mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.

Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Arigenx Therapeutics Co. Ltd. has divulged substituted pyrimidine hydrazide compounds acting as aryl hydrocarbon receptor (AhR) antagonists reported to be useful for the treatment of cancer.

Daiichi Sankyo Co. Ltd. and Kyoto Pharmaceutical Industries Ltd. have identified Kelch-like ECH-associated protein 1 (Keap1)/Nrf2 interaction inhibitors reported to be useful for the treatment of acute lung injury, chronic kidney disease, autism, Alzheimer's disease, dry eye, heart failure, psoriasis and Sjögren's syndrome, among others.

Erasca Inc. has synthesized tricyclic pyridones and pyrimidones acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Astrazeneca AB has disclosed bicyclic heteroaromatic compounds acting as transcriptional enhancer factor (TEAD) and TEAD-4 inhibitors reported to be useful for the treatment of cancer.

Graviton Bioscience BV has described Rho kinase 2 (ROCK 2; ROCKα) inhibitors reported to be useful for the treatment of cancer, fibrosis, autoimmune, lung, cardiovascular, eye, inflammatory and neurological disorders.

Brise Pharmaceutical (Shanghai) Co. Ltd. has divulged calcitonin gene-related peptide receptor (CALCRL; CGRPR) antagonists reported to be useful for treatment of cerebrovascular and vascular disorders.

Novacell Technology Inc. has identified peptides acting as N-formyl peptide receptor 2 (FPR2; FPRL1; LXA4) agonists reported to be useful for the treatment of cancer, inflammatory and immunological disorders.